Highest-materiality recent filing
Encompass Health issues $500M 5.875% notes due 2034; to redeem $400M of 4.500% notes due 2028
Issued $500M 5.875% Senior Notes due 2034 at par; net proceeds ~$491.2M after discounts and expenses.
Encompass Health prices $500M of 5.875% senior notes due 2034 to refinance debt
Issued $500M aggregate principal of 5.875% senior notes due 2034; closing expected May 29, 2026.
Encompass Health annual meeting: all director nominees elected, PwC ratified, say-on-pay approved
All 10 director nominees elected; Mark J. Tarr received highest votes (85.9M for, 0.6M against).
Encompass Health files 8-K for Q1 2026 earnings; no specific results in filing body
Filing references press release (Ex-99.1) and supplemental slides (Ex-99.2) for Q1 2026 results.
Encompass Health enters $1B revolver with Truist; matures 2031, replaces 2022 facility
New $1.0B revolving credit facility with Truist Bank as administrative agent; maturity extended to March 9, 2031 (from Oct 2027).
Encompass Health appoints Cain Hayes to two board committees
Cain Hayes appointed to Compensation and Human Capital Committee.
Encompass Health Reports Q4 and Full Year 2025 Financial Results
Press release dated February 5, 2026, covers three months and year ended December 31, 2025.
Encompass Health elects Cain A. Hayes as independent director
Cain A. Hayes elected to Encompass Health Board effective January 30, 2026.
Encompass Health reaffirms full-year 2025 guidance ahead of investor meetings
Net operating revenue expected $5,905M to $5,955M.
Encompass Health reports Q3 2025 results; specific figures not available in filing excerpt
Press release and supplemental slides for Q3 2025 furnished; no revenue or EPS extracted from provided text.
Director Patricia Maryland retires from Encompass Health board for health reasons
Patricia Maryland resigned from the board effective September 17, 2025, citing health reasons.
Encompass Health reaffirms FY2025 guidance during investor meetings
Net operating revenue guidance of $5.88B-$5.98B for FY2025.
Encompass Health Q2 2025 results filed; specific figures in exhibits not provided in text
Press release for Q2 2025 results issued on August 4, 2025, but no financial data appears in the filing body.
Encompass Health publishes Investor Reference Book with business overview and strategy
Investor Reference Book published June 25, 2025, covering company overview, industry, business outlook, growth strategy, and operational initiatives.
Encompass Health reaffirms FY2025 guidance ahead of investor meetings
Reiterated FY2025 net operating revenue $5,850M-$5,925M.
Encompass Health shareholders approve 2025 Omnibus Incentive Plan; re-elect all 10 directors
93.9% of shares represented at meeting; each director nominee received >96% votes for.
Encompass Health appoints Patrick Tuer as EVP/COO; Q1 earnings filed without specific figures
Patrick Tuer (41) named EVP & COO effective April 24, 2025; previously Group President overseeing 69 hospitals.
Encompass Health boosts CEO 2025 base salary to $1.1M, aircraft allowance to $100K
CEO Mark Tarr: 2025 base salary $1.1M (+4.8%), target cash bonus $1.485M, target equity $6M.
Earnings press release (Ex 99.1) and supplemental slides (Ex 99.2) referenced but not included in filing text.
Encompass Health reports Q3 2024 earnings; details not available in exhibits
Press release issued on October 28, 2024 for three and nine months ended September 30, 2024.
Encompass Health reports Q2 2024 results; specifics unavailable in filing text
Encompass Health issued press release on Aug 5, 2024 covering Q2 2024 financial results.
Encompass Health publishes Investor Reference Book covering business outlook and growth strategy
Investor Reference Book published June 21, 2024 includes overview, business outlook, growth strategy, and operational initiatives.
Reiterated full-year 2024 net operating revenue guidance of $5,250M to $5,325M.
Encompass Health shareholders elect directors, approve executive pay; Greg Carmichael named Chairman
All 10 board nominees elected with ~88-89M votes for; 4.9M broker non-votes on advisory items.
Encompass Health reports Q1 2024 earnings; figures not extractable from provided text
The 8-K references a press release (Exhibit 99.1) and supplemental slides (Exhibit 99.2) for Q1 2024 results.
Encompass Health reiterates FY2024 guidance at Barclays conference; no changes
Company to present at Barclays Global Healthcare Conference on March 12, 2024, with CEO and CFO.
Encompass Health boosts CEO target LTI to $5.425M, GC salary to $625K
Board approved increase in CEO Mark Tarr's target long-term incentive from $5.17M to $5.425M.
Encompass Health discloses cyber incident at vendor Change Healthcare affecting claims
Received notice Feb 21, 2024 from Change Healthcare (UnitedHealth subsidiary) of a cybersecurity incident.
Encompass Health reports Q4 and FY 2023 results; no specific figures in filing text
Q4 and full-year 2023 financial results announced on Feb 7, 2024.
Encompass Health appoints Edward M. Christie III to Board, expanding to 12 members
Edward M. Christie III appointed as independent director, effective Nov 27, 2023.
Encompass Health reports Q3 2023 results; specific financial data not provided in filing text
Encompass Health issued a press release on Oct 26, 2023, reporting Q3 2023 results.
Encompass Health reaffirms 5-year growth targets; RCD affirmation >95% in Alabama
Five-year targets (2023-27): 6-10 de novos/year, 80-120 bed additions/year, 6-8% discharge CAGR.
Encompass Health reports Q2 2023 earnings; details unavailable in provided text
Filing states press release and supplemental information attached as Exhibits 99.1 and 99.2.
Encompass Health adopts clawback policy to comply with SEC Rule 10D-1 and NYSE listing standards
Board approved amended clawback policy on July 20, 2023, requiring mandatory recovery of erroneous incentive-based compensation from current and former executive officers upon accounting restatement.
Encompass Health publishes Investor Reference Book with business overview and growth strategy
Reference book covers company overview, industry landscape, business outlook, and growth strategy.
Encompass Health reiterates FY2023 guidance at investor meeting on May 22
Reaffirms FY2023 net operating revenue of $4,700M-$4,770M.
Encompass Health holds 2023 annual meeting; all director nominees elected, say-on-pay approved
All 11 director nominees elected with >80M votes for each; top vote-getter Mark Tarr at 86.3M.
Encompass Health reports Q1 2023 earnings; specific results not available in filing text
Company issued press release for Q1 2023 financial results on April 27, 2023.
Encompass Health reiterates FY2023 guidance; Q1 rehab discharge growth strong through February
Reaffirms FY2023 net operating revenue guidance of $4.68B-$4.76B and adjusted EBITDA of $860M-$900M.
LTIP awards now include relative TSR modifier: 75th percentile multiplies shares by 1.25 (capped at 200% of target), 25th percentile by 0.75.
Encompass Health corrects EPOB sensitivity and Owasso de novo bed count
Clarified that a 0.01 change in employees per occupied bed impacts annual Adj. EBITDA by $6-$8M, not 0.05.
Encompass Health files Q4/FY 2022 results; provides Q1 2023 trend update
Inpatient rehabilitation discharge growth remained strong in January 2023.
Encompass Health amends bylaws with universal proxy, exclusive forum, virtual meeting provisions
Stockholder nominees must comply with SEC Rule 14a-19; noncompliance disqualifies nominees.
Encompass Health reaffirms FY2022 guidance at Mizuho CEO Insight Series
Reiterates FY2022 net operating revenues guidance of $4.32B to $4.35B.
Encompass Health files Q3 2022 earnings 8-K; no specific results in provided text
Filing body contains only non-GAAP definitions and forward-looking statements; no earnings numbers are present.
Encompass Health enters $1B revolving credit facility; maturity extended to 2027
Sixth Amended and Restated Credit Agreement dated Oct 7, 2022; revolving maturity extended to Oct 7, 2027.
Encompass Health files Q2 2022 results; specific figures not available in provided text
Filing references press release (Ex-99.1) and supplemental slides (Ex-99.2), but exhibit content not appended.
Encompass Health completes spin-off of home health/hospice business into Enhabit
Distribution effective July 1, 2022; one Enhabit share for every two EHC shares held on June 24, 2022.
Form 10 for Enhabit, Inc. became effective June 17, 2022; final information statement issued June 21.
Encompass Health holds virtual non-deal roadshow for Enhabit segment
Enhabit CEO Barbara Jacobsmeyer and CFO Crissy Carlisle to present at virtual roadshow starting June 13, 2022.
On April 24, 2025, Encompass Health issued a press release announcing the appointment of Patrick W. Tuer as Executive Vice President and Chief Operating Officer
the appointment of Edward M. Christie III as director to fill the newly created vacant seat.
the appointment of Kevin J. O’Connor as director
the appointment of Christopher R. Reidy as director.
On August 31, 2021, the Board of Directors (the “Board”) of Encompass Health Corporation (the “Corporation”), unanimously approved, effective as of October 1, 2021, an increase in the number of directors constituting the Board of the Corporation from 14 to 15 and, upon the recommendation of its Nominating/Corporate Governance Committee, the appointment of Christopher R. Reidy as director to fill the newly created vacant seat.
Max materiality 0.80 · Median 0.35 · Most common event other_material